• Explore /
  • Poster
  • / Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).

Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).

Abstract Poster

Authors

Pasquale Rescigno

Pasquale Rescigno

The Institute of Cancer Research, London, United Kingdom

Pasquale Rescigno , Maria Dolores Fenor de la Maza , Stephanie M. Burnett , Guillermo Villacampa , Morgaine Stiles , Fay Helen Cafferty , Nick Beije , Suzanne Carreira , Ines Figueiredo , Penelope Flohr , Bora Gurel , Claudia Bertan , Daniel Westaby , Khobe Chandran , Mateus Crespo , Carla Perna , Nina Tunariu , Adam Sharp , Christina Yap , Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03506997

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 138)

DOI

10.1200/JCO.2024.42.4_suppl.138

Abstract #

138

Poster Bd #

F9

Abstract Disclosures

Similar Posters

First Author: Thiago Bueno Oliveira Sr.

First Author: Padmanee Sharma

First Author: Vivek Narayan

First Author: Stephen Lam Chan